EVFM
Evofem Biosciences, Inc.Company with tickers: EVFM
CIK
1618835
CUSIP
30048L302
Shares Outstanding
132,530,081
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $899,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | — | ||||
| Operating Income | $-4,569,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-5,465,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.04 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.04 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2022-12-31 | 2023-12-31 |
|---|---|---|
| Phexxi | $16,800,000 | $18,200,000 |